. Author manuscript; available in PMC: 2015 Sep 1.

Published in final edited form as: Kidney Int. 2014 Sep 17;87(3):640–648. doi: 10.1038/ki.2014.301

Table 3b. Combined Model Using both Clinical + Biomarker Model^* for Prediction of Persistent Doubling of Serum Creatinine, Dialysis, or Death.

Variable	OR	95% CI
Clinical Model +:
uNGAL	1.4	0.8-2.5
uL-FABP	2.3	1.4-3.8
uIL-18	1.4	0.9-2.2
uKIM-1	1.5	0.8-2.7

Abbreviations: OR, odds ratio; CI, confidence interval; uNGAL, urine neutrophil gelatinase-associated lipocalin; uL-FABP, urine L-type fatty acid binding protein; uIL-18, urine Interleukin-18; uKIM-1, urine Kidney Injury Molecule-1.

Biomarkers were log₁₀ transformed. ORs are represented per interquartile range based on biomarker concentration.

Adjusted for age, APACHE II score, serum creatinine at KDIGO Stage I, and presence or absence of sepsis at baseline

Table 3b. Combined Model Using both Clinical + Biomarker Model* for Prediction of Persistent Doubling of Serum Creatinine, Dialysis, or Death.

Table 3b. Combined Model Using both Clinical + Biomarker Model^* for Prediction of Persistent Doubling of Serum Creatinine, Dialysis, or Death.